Search NLS News

Immunovia has appointed Jeff Borcherding as CEO of its US subsidiary Immunovia, Inc. Jeff Borcherding will be part of the Immunovia group management team from April 11. “I’m very pleased that Jeff Borcherding will join Immunovia. Jeff’s appointment further accelerates the US commercialization efforts of IMMray PanCan-d and is in-line with our strategic priority to […]

LINK Medical is currently preparing to work in line with the Clinical Trial Regulation, going into effect on the 31st of January 2022. The new regulation will replace the Clinical Trials Directive 2001/20/EC and aims to ensure a higher level of harmonization of the rules for authorizing and conducting clinical trials throughout the EU thus […]

EXACT Therapeutics has announced that its Board of Directors has appointed Per Walday as Chief Executive Officer. Per Walday has experience from research to commercialization of therapeutics and medical devices globally, including drug-device combination within the field of oncology. “The Board and I are very excited to welcome Per as CEO of EXACT-Tx. He brings […]

Atrogi has received approval from the German authority BfArM to initiate a phase 1 study with their small molecule drug candidate ATR-258 in healthy volunteers and type 2 diabetics. The trial is expected to be completed by year end 2022 with the final report in Q1/2,2023. “Following extensive pre-clinical work, the first study in humans […]

Finnish DelSiTech and Swiss-based Optifye Therapeutics have announced an exclusive licensing agreement pertaining to the development of controlled-release dexamethasone eye drops utilizing DelSiTech Silica Matrix technology. Controlled release of dexamethasone eye drops, based on DelSiTech Silica Matrix technology, is an eye drop product that is applied as a single drop, once daily under the eye […]

Ondexxya has been approved in Japan for patients treated with the Factor Xa (FXa) inhibitors apixaban, rivaroxaban or edoxaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. The approval by the Japanese Ministry of Health, Labour and Welfare was based on positive results from the ANNEXA-4 Phase III clinical trial showing […]

The company has secured a private placement, to existing and new investors, led by Flerie Invest AB. The purpose of the issue is primarily to finance the company’s clinical development in multiple myeloma and other indications. The company’s lead investigational candidate drug is currently being evaluated in combination with Sanofi’s anti-CD38 antibody Sarclisa (Isatuximab) in […]

The Board of Directors of SynAct Pharma has resolved to carry out a new issue of shares with preferential rights for existing shareholders of approximately 150 million SEK before issue costs, guaranteed to 100 percent. In addition, the Board of Directors may, based on the authorization granted by the annual general meeting on 21 May […]

Orion is planning to change and refocus the strategy of its R&D function and in the future focus would be on cancer and pain. Orion will initiate negotiations concerning in total 430 salaried employees and senior salaried employees in Finland in Espoo, Turku and Kuopio in the research areas in which investment would be discontinued […]

Vicore Pharma Holding has announced plans to initiate a clinical trial with C21 in Pulmonary arterial hypertension. Pulmonary arterial hypertension (PAH) is a rare lung disease with huge unmet medical need where existing medicines reduce the pressure by dilating the vessels without changing underlying disease or survival, describes the company. Both PAH and the pulmonary […]